Literature DB >> 18639493

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.

Mert Erkan1, Christoph W Michalski, Simon Rieder, Carolin Reiser-Erkan, Ivane Abiatari, Armin Kolb, Nathalia A Giese, Irene Esposito, Helmut Friess, Jörg Kleeff.   

Abstract

BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with an innate resistance to therapy. Pancreatic stellate cells (PSCs) produce this excessively desmoplastic microenvironment. The impact of PSC activity on PDAC behavior in vivo is analyzed.
METHODS: 233 patients who underwent surgery for PDAC were evaluated by immunohistochemistry using antibodies against alpha-smooth muscle actin as a marker of PSC activity. Aniline was used to stain collagen deposition. The ratio of alpha-smooth muscle actin-stained area to collagen-stained area was defined as the activated stroma index (ASI). Survival analysis was performed using the Kaplan-Meier method. Prognostic factors were determined in a multivariable analysis using a Cox proportional hazards model.
RESULTS: Four major patterns of collagen deposition were defined with regard to PSC activity. The combination of high stromal activity and low collagen deposition was associated with a worse prognosis, whereas the combination of high collagen deposition and low stromal activity indicated a better prognosis. Patients with the lowest ASI had the best median survival rate (25.7 mo). The highest ASI was found in patients with the worst median survival rate (16.1 mo; P = .007; lowest vs highest ASI: hazard ratio, 1.61; 95% confidence interval, 1.014-2.562). ASI was an independent prognostic marker in multivariable survival analysis comparable with the nodal status of cancer.
CONCLUSIONS: The activated stroma index is a novel independent prognostic marker in PDAC in cases undergoing surgery. This finding highlights the impact of the microenvironment in cancer progression and on patient survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639493     DOI: 10.1016/j.cgh.2008.05.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  168 in total

1.  PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker.

Authors:  Sayaka Yuzawa; Mitsunobu R Kano; Takahiro Einama; Hiroshi Nishihara
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

2.  Tie1 deficiency induces endothelial-mesenchymal transition.

Authors:  Julie Garcia; Maria José Sandi; Pierre Cordelier; Bernard Binétruy; Jacques Pouysségur; Juan Lucio Iovanna; Roselyne Tournaire
Journal:  EMBO Rep       Date:  2012-05-01       Impact factor: 8.807

Review 3.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

4.  Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma.

Authors:  Yuanke Li; Zhen Zhao; Hao Liu; John Peter Fetse; Akshay Jain; Chien-Yu Lin; Kun Cheng
Journal:  ACS Appl Mater Interfaces       Date:  2019-11-26       Impact factor: 9.229

5.  A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma.

Authors:  Chun-Te Chen; Yi-Chun Chen; Yi Du; Zhenbo Han; Haoqiang Ying; Richard R Bouchard; Jennifer L Hsu; Jung-Mao Hsu; Trevor M Mitcham; Mei-Kuang Chen; Hui-Lung Sun; Shih-Shin Chang; Donghui Li; Ping Chang; Ronald A DePinho; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

6.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Authors:  Berna C Özdemir; Tsvetelina Pentcheva-Hoang; Julienne L Carstens; Xiaofeng Zheng; Chia-Chin Wu; Tyler R Simpson; Hanane Laklai; Hikaru Sugimoto; Christoph Kahlert; Sergey V Novitskiy; Ana De Jesus-Acosta; Padmanee Sharma; Pedram Heidari; Umar Mahmood; Lynda Chin; Harold L Moses; Valerie M Weaver; Anirban Maitra; James P Allison; Valerie S LeBleu; Raghu Kalluri
Journal:  Cancer Cell       Date:  2014-05-22       Impact factor: 31.743

7.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

8.  Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer.

Authors:  Qian Zhang; Chunwei Peng
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

Review 9.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

10.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.